Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALTITUDE NASH: A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis Stage 3 Fibrosis

NCT05461105 is registered in ClinicalTrials.gov with Hepion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05461105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05461105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALTITUDE NASH: A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis Stage 3 Fibrosis
Lead sponsor
Hepion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 15, 2022
Completion date
July 7, 2023
Enrollment
60 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

nash with fibrosis